期刊文献+

顺铂增强替尼泊甙杀伤小细胞肺癌细胞系的作用

Enhancement of cisplatin on cytocidal effect of tineposide against small cell lung cancer cell line
下载PDF
导出
摘要 目的通过顺铂(CDDP)与替尼泊甙(VM-26)联合作用,探讨顺铂增强替尼泊甙对小细胞肺癌细胞株杀伤作用的机制。方法用MTT法,测定H446小细胞肺癌细胞24 h抑制率;AO/EB双荧光染色观察细胞活率;琼脂糖凝胶电泳检测DNA断裂条带;半定量RT-PCR及蛋白印迹检测DNA拓扑异构酶Ⅱ(TopoⅡ)及特化蛋白1(SP1)的表达。结果CDDP与VM-26联合应用有明显的协同效应;二药合用与单独用药相比,细胞活率明显降低,DNA损伤程度增加。H446细胞经CDDP单独作用可以促进SP1、TopoⅡα和TopoⅡβmRNA及蛋白的表达;经VM-26单独作用后,TopoⅡα和TopoⅡβmRNA及蛋白表达降低,而SP1表达无明显改变;二药合用后可见TopoⅡαmRNA及蛋白的表达比单独应用CDDP下调,SP1 mRNA及蛋白的表达比单用VM-26升高,但与单用CDDP相比没有明显变化。结论CDDP通过上调SP1促进H446细胞中TopoⅡ表达,为TopoⅡ抑制剂类药物VM-26提供更多的作用靶点,能够明显提高对小细胞肺癌的抑制作用。 Objective To investigate the mechanism of cisplatin enhanceing the effect of tineposide killing small cell lung cancer cell line by combination of the two drug. Methods The microeulture tetrazolium (MTT) assay was used to determine the inhibition rates of CDDP combined with VM-26. Acridine orange/ethidium bromide (AO/EB) fluorescent staining was used to show the cell vitality rates, DNA disruption ladder were applied to reveal cell apoptosis. The mRNA and protein level of topoisomerase Ⅱ(Topo Ⅱ ) and transcript factor SP1 were measured by semi-quantitative RT-PCR and western blot. Results There is synergistic effect between the two drug. The cell vitality rates were decreased in combination group than that of CDDP or VM-26 used alone, the corn- bination treatment group resulted in more serious DNA strand breakage. The expression of Topo Ⅱα, β and SP1 mRNA and protein both increased in CDDP treatment group, while the Topo Ⅱα,β expression decreased and the SP1 expression has no obviously change in VM-26 treatment group. In combination group, Topo Ⅱα expression were decreased comparing with CDDP used has no obviously change as comparing with sion through up-regulating SP1 expression, small cell lung cancer cell. alone, SP1 expression increased comparing with VM-26 used alone, but CDDP used alone. Conclusion CDDP could enhance Topo Ⅱ expreswhich offer more target for Topo Ⅱ inhibitor VM-26 to act on killing
出处 《基础医学与临床》 CSCD 北大核心 2006年第11期1229-1234,共6页 Basic and Clinical Medicine
关键词 小细胞肺癌 顺铂 替尼泊甙 拓扑异构酶Ⅱ 特化蛋白1 small cell lung cancer cisplatin tineposide topoisomerase Ⅱ specificity protein-1
  • 相关文献

参考文献11

  • 1Figoli F,Seleni VC,Maggian P,et al.Cisplatin and VM26combination:an effective regimen for small cell lung cancer especially with brain metastases[J].Proc Am Soc Clin Oncol,1989,8:234-239.
  • 2罗莉霞,李平华,彭惠,骆云鹏,汤为学.羟基喜树碱抑制体外培养兔晶体上皮细胞的生长[J].基础医学与临床,2001,21(4):358-360. 被引量:1
  • 3戴体俊.合并用药的定量分析[J].中国药理学通报,1998,14(5):479-480. 被引量:136
  • 4陈小义,徐瑞成,陈莉,张敏,卢青,吴晓霞.蟾蜍灵诱导人胃癌细胞凋亡的实验研究[J].基础医学与临床,2000,20(5):50-53. 被引量:25
  • 5牛晨晨,李俊发,徐群渊.重复低氧对小鼠脑内cPKCα和γ膜转位及蛋白表达的影响[J].基础医学与临床,2005,25(1):30-34. 被引量:6
  • 6Koshiyama M,Fujii H,Kinezaki M,et al.Correlation between Topo Ⅱ alpha expression and chemosensitivity testing for Topo Ⅱ-targeting drugs in gynaecological carcinomas[J].Anticancer Res,2001,21:905 -910.
  • 7Sabourin M,Osheroff N,Kohno K,et al.Sensitivity of human type Ⅱ topoisomerases to DNA damage:stimulation of enzyme-mediated DNA cleavage by abasic,oxidized and alkylated lesions[J].Nucleic Acids Res,2000,28:1947-1954.
  • 8James TK,Kristin RC,Frank RM,et al.Isolation of cDNA encoding transcription factor SP1 and functional analysis of the DNA binding domain[J].Cell,1987,51:1079 -1090.
  • 9Minagawa Y,Kigawa J,Irie T,et al.Enhanced topoisomerase Ⅰ activity and increased topoisomerase Ⅱ alpha content in cisplatin-resistant cancer cell lines[J].Jpn J Cancer Res,1997,88:1218-1223.
  • 10Eder JP Jr,Chan VT,Ng SW,et al.DNA topoisomerase Ⅱ alpha expression is associated with alkylating agent resistance[J].Cancer Res,1995,55:6109-6116.

二级参考文献22

  • 1温汉平,王小宁.肿瘤细胞体外药敏试验MTT分析法[J].中华肿瘤杂志,1993,15(6):470-471. 被引量:63
  • 2田普训,南勋义,李旭,张学斌.蟾酥脂质体对人膀胱移行细胞癌BIU-87作用的体外实验研究[J].中华泌尿外科杂志,1994,15(6):432-435. 被引量:14
  • 3耿宝琴.紫杉醇类与喜树碱类的研究进展[J].实用肿瘤杂志,1995,10(4):199-201. 被引量:19
  • 4Tsouka V, Markou T, Lazou A. Differential effect of ischemic and pharmacological preconditioning on PKC isoform translocation in adult rat cardiac myocytes[J]. Cell Physiol Biochem, 2002, 12: 315-324.
  • 5Cross HR, Murphy E, Bolli R, et al. Expression of activated PKC epsilon (PKC epsilon) protects the ischemic heart, without attenuating ischemic H(+) production [J]. J Mol Cell Cardiol, 2002, 34: 361-367.
  • 6Kurkinen K, Busto R, Goldsteins G, et al. Isoform-specific membrane translocation of protein kinase C after ischemic preconditioning [J]. Neurochem Res, 2001,26: 1139-1144.
  • 7Simonis G, Weinbrenner C, Strasser RH. Ischemic preconditioning promotes a transient, but not sustained translocation of protein kinase C and sensitization of adenylyl cyclase [J]. Basic Res Cardiol, 2003,98:104-113.
  • 8Wu J, Li J(李俊发), Huang KP, et al. Attenuation of protein kinase C and cAMP-dependent protein kinase signal transduction in the neurogranin knockout mouse[J]. J Biol Chem, 2002, 277: 19498-19505.
  • 9Liu H, Zhang HY, Zhu X, et al. Preconditioning blocks cardiocyte apoptosis: role of K(ATP) channels and PKC-epsilon [J]. Am J Physiol Heart Circ Physiol, 2002, 282: H1380-H1386.
  • 10Matthews SA, Dayalu R, Thompson LJ,et al. Regulation of protein kinase Cnu by the B-cell antigen receptor[J]. J Biol Chem, 2003, 278: 9086-9091.

共引文献164

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部